Linda Stocum, Associate Editor

This week's edition of the Mainstream Patients features stories about removing skin tags at home, plum oil for skin and hair, and more.

In this interview, Andrew Blauvelt, MD, MBA, explains how nurse practitioners (NPs) can better counsel psoriasis patients and why its important that NPs have the top knowledge on current dermatologic treatments.

A breakfast product theater at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, sponsored by Sanofi and Regeneron Pharmaceuticals, dove into the different manifestation of atopic dermatitis in skin of color and how to better recognize the disease in this patient population.

In the world of pediatric dermatology, many skin conditions can have parents concerned about their children’s condition. Lisa Swanson, MD, explains how to better address their questions at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium.

In this video interview, Andrew Blauvelt, MD, MBA, dives into the current state of atopic dermatitis treatment from his talk presented at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.

In her presentation at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, Lisa Swanson, MD, discussed the important updates in pediatric dermatology, including early life interventions, food allergies, and more.

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.

ICYMI, this week we had stories on DAXI's BLA resubmission approval, sexual dysfunction and atopic dermatitis, and more.

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Scientists from Mount Sinai have reported that a mutation of the ARID2 gene may be a key factor in the risk of melanoma turning metastatic.

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee.

Jonathan Silverberg, MD, the associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, joins us to discuss a poster from the December 2021 RAD conference.

In this video interview, Darren Smith, MD, comments on the Renuvion/J-Plasma device (Apyx Medical) receiving an FDA warning for dermal resurfacing or skin contraction. He dives into how the device may be causing these issues, how this affects patients, and more.

This week's edition of the Mainstream Patients features stories about the causes of eczema, botox for TMJ, and more.

ICYMI, this week we had stories on physician assistants, diverse perspectives in aesthetic medicine, and more.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.

ICYMI, this week we had stories on physician assistants, diverse perspectives in aesthetic medicine, and more.

The results from the Evelo Biosciences EDP1815 treatment provide the first demonstration in a phase 2 trial of the safety and efficacy of an orally-administered, gut-restricted SINTAX medicine.

The company reported positive results from the PEARL-1 clinical phase 1 study regarding KB301 as an investigational gene-based treatment to address the underlying biology of aging skin.

LEO Pharma presented long-term data from an interim analysis of its ECZTEND 5-year extension trial, showing no new safety signals.

Nearly all survey takers reported wanting topical treatment options that are more effective, not steroids, and simpler to use.

Terri Phillips, MD, FAAP, expands on her letter to the editor in the April issue of Dermatology Times® diving into how her experience has shaped the her view of the aesthetics industry, the challenges both physicians and patients face, and more.

The skincare manufacturer and distributer announced that it has received patents for hair growth and melasma.

Take a look back at our most popular news from March 2022.

This week's edition of the Mainstream Patients features stories about the difference between a sun burn and sun poisoning, micro-coring, and more.

ICYMI, this week we had stories on the latest coverage from the 2022 American Academy of Dermatology Annual meeting, our newest drug pipeline video and more.

A poster from the 2022 American Academy of Dermatology Annual Meeting gathered the real-world data around patients using dupilumab to treat atopic dermatitis.

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.